HF I/II (n = 25) | HF III/IV (n = 23) | p-value | |
---|---|---|---|
Age (years) | 63 ± 13 | 66 ± 11 | 0.359 |
Gender, n (%) | 0.407 | ||
Male | 16 (64.0) | 13 (56.5) | |
Female | 9 (36.0) | 10 (43.5) | |
BMI (Kg/m2) | 28 ± 5 | 24 ± 4 | 0.041 |
Coronary artery disease, n (%) | 14 (56.0) | 7 (30.4) | 0.067 |
Ischemic heart disease, n (%) | 9 (36.0) | 4 (17.4) | 0.130 |
Hypertension, n (%) | 16 (64.0) | 15 (65.2) | 0.585 |
Diabetes mellitus, n (%) | 7 (28.0) | 4 (17.4) | 0.300 |
Hyperlipidemia, n (%) | 10 (40.0) | 3 (13.0) | 0.036 |
HF etiology, n (%) | |||
Hypertension | 7 (28.0) | 8 (34.8) | 0.422 |
Ischemic | 9 (36.0) | 4 (17.4) | 0.130 |
Dilated cardiomyopathy | 6 (24.0) | 7 (30.4) | 0.430 |
Myocarditis | 3 (12.0) | 2 (8.7) | 0.541 |
Idiopathic | 0 (0) | 2 (8.7) | 0.224 |
Medication, n (%) | |||
ACE inhibitors | 20 (80.0) | 21 (91.3) | 0.244 |
Beta blockers | 13 (52.0) | 17 (73.9) | 0.102 |
Aldosterone antagonists | 4 (16.0) | 22 (95.7) | < 0.001 |
Diuretics | 16 (64.0) | 15 (65.2) | 0.585 |
Antiplatelet | 13 (52.0) | 7 (30.4) | 0.111 |
Anticoagulants | 1 (4.0) | 3 (13.0) | 0.273 |
Antiarrhythmic | 7 (28.0) | 0 (0.0) | 0.007 |
Metformin | 9 (36.0) | 6 (26.1) | 0.335 |
Statina | 10 (40.0) | 3 (13.0) | 0.036 |